Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in Prurigo Nodularis
NCT06424470Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Jun 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in prurigo nodularis (PN), sponsored by Keymed Biosciences. Started Jun 2024; status: completed.
02
Drugs
stapokibart
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06424470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424470.